0001493152-26-019773
SEC filingTelomir Pharmaceuticals announced FDA clearance of its IND application for Telomir-Zn in triple-negative breast cancer, enabling initiation of a first-in-human Phase 1/2 clinical trial in the first half of 2026 to evaluate safety, tolerability, and preliminary efficacy including objective response rate as the primary endpoint.
This FDA IND clearance represents a critical inflection point for Telomir Pharmaceuticals, marking the transition from preclinical development to human clinical evaluation for Telomir-Zn — its lead candidate in triple-negative breast cancer, a high-unmet-need oncology indication with limited treatment options. The clearance confirms the FDA’s acceptance of the preclinical pharmacology, toxicology, pharmacokinetic, manufacturing, and clinical protocol package, reducing near-term regulatory risk. The planned Phase 1/2 trial design — with explicit safety-driven Phase 1 objectives and ORR as the Phase 2 primary endpoint — aligns with FDA expectations for early oncology development and positions the company to generate interpretable efficacy signals within a defined patient cohort. Enrollment of approximately 76 patients across both phases suggests a streamlined, efficient study likely intended to support future discussions around accelerated development pathways. The inclusion of a comprehensive translational biomarker program — spanning epigenetic regulation, gene expression, histone modifications, and telomere biology — not only strengthens biological plausibility but also creates potential for identifying predictive biomarkers that could inform later-stage trial design or regulatory strategy. As no financial terms, partnerships, or capital events are disclosed, the materiality stems entirely from clinical progression velocity and de-risking of the development path.